Biopsychosocial factors should be considered when evaluating central sensitization in axial spondyloarthritis
Rheumatology International · 26.03.2023 · 43 (5) · 923-932
DOI: 10.1007/s00296-023-05317-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology International, online erschienen am 26.03.2023. Verfasst von Aylin Sariyildiz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Cukurova University, Adana, Turkey. aylingoksen@hotmail.com. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
To identify the determinants of central sensitization (CS) in patients with axial spondyloarthritis (axSpA). Central Sensitization Inventory (CSI) was used to determine CS frequency. Disease-related variables including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP/-ESR), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) and Numeric Rating Scale (NRS)GLOBAL were assessed. Biopsychosocial variables were evaluated by the Multidimensional Scale of Perceived Social Support (MSPSS), Brief Illness Perception Questionnaire (B-IPQ), Hospital Anxiety and Depression Scale (HADS) and subscales for Anxiety (HADS-A) and Depression (HADS-D), and Jenkins Sleep Evaluation Scale (JSS). To determine the predictors of the development and severity of CS, multiple linear and logistic regression analyses were performed. The frequency of CS was 57.4% in the study population (n = 108). CSI score was correlated with the duration of morning stiffness, BASDAI, ASDAS-CRP, ASDAS-ESR, NRSGLOBAL, BASFI, MASES, ASOoL, JSS, HADS, and B-IPQ total scores (ρ ranged from 0.510 to 0.853). Multiple regression analysis indicated that BASDAI (OR: 10.44, 95% CI: 2.65-41.09), MASES (OR: 2.47, 95% CI: 1.09-5.56) and HADS-A (OR: 1.62, 95% CI: 1.11-2.37) were independent predictors of the development of CS. Additionally, higher NRSGLOBAL, JSS, HADS-D, and HADS-A scores appeared to determine the severity of CS. This study confirms that worse disease activity, more enthesal involvement, and anxiety independently predict the development of CS. Additionally, higher patient-perceived disease activity, sleep impairment and poor mental health significantly contribute to the severity of CS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Cukurova University, Adana, Turkey. aylingoksen@hotmail.com.
- Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Cukurova University, Adana, Turkey.
- Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Cukurova University, Adana, Turkey.
- Faculty of Medicine, Department of Biostatistics, Cukurova University, Adana, Turkey.
ORCID-Profile: Aylin Sariyildiz, Ilke Coskun Benlidayi, Ipek Turk, Serife Seyda Zengin Acemoglu, Ilker Unal
Zitieren
APA
Sariyildiz, A., Coskun Benlidayi, I., Turk, I., Zengin Acemoglu, S. S., & Unal, I. (2023). Biopsychosocial factors should be considered when evaluating central sensitization in axial spondyloarthritis. Rheumatology International, 43(5), 923-932. https://doi.org/10.1007/s00296-023-05317-2
Vancouver
Sariyildiz A, Coskun Benlidayi I, Turk I, Zengin Acemoglu SS, Unal I. Biopsychosocial factors should be considered when evaluating central sensitization in axial spondyloarthritis. Rheumatology International. 2023;43(5):923-932. doi:10.1007/s00296-023-05317-2
BibTeX
@article{Sariyildiz2023,
author = {Sariyildiz, Aylin and Coskun Benlidayi, Ilke and Turk, Ipek and Zengin Acemoglu, Serife Seyda and Unal, Ilker},
title = {Biopsychosocial factors should be considered when evaluating central sensitization in axial spondyloarthritis},
journal = {Rheumatology International},
year = {2023},
volume = {43},
number = {5},
pages = {923--932},
doi = {10.1007/s00296-023-05317-2}
}
EUVIMED